Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L. Reuteri for NEC prevention in preterm infants
NCT04541771Phase 2Unknown
- Sponsor
- Children's Hospital and Institute of Child Health Multan
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 2, randomised, double-blind trial of Lactobacillus reuteri DSM 17938 in necrotizing enterocolitis (NEC) (2 arms), sponsored by Children's Hospital and Institute of Child Health Multan. Primary endpoint: Necrotizing Enterocolitis. Status: unknown.
02
Drugs
Lactobacillus reuteri DSM 17938
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT04541771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541771.